Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study

被引：0

作者：

Mara Persano

Margherita Rimini

Toshifumi Tada

Goki Suda

Shigeo Shimose

Masatoshi Kudo

Jaekyung Cheon

Fabian Finkelmeier

Ho Yeong Lim

Lorenza Rimassa

José Presa

Gianluca Masi

Changhoon Yoo

Sara Lonardi

Francesco Tovoli

Takashi Kumada

Naoya Sakamoto

Hideki Iwamoto

Tomoko Aoki

Hong Jae Chon

Vera Himmelsbach

Tiziana Pressiani

Takumi Kawaguchi

Margarida Montes

Caterina Vivaldi

Caterina Soldà

Fabio Piscaglia

Atsushi Hiraoka

Takuya Sho

Takashi Niizeki

Naoshi Nishida

Christoph Steup

Massimo Iavarone

Giovanni Di Costanzo

Fabio Marra

Mario Scartozzi

Emiliano Tamburini

Giuseppe Cabibbo

Francesco Giuseppe Foschi

Marianna Silletta

Masashi Hirooka

Kazuya Kariyama

Joji Tani

Masanori Atsukawa

Koichi Takaguchi

Ei Itobayashi

Shinya Fukunishi

Kunihiko Tsuji

Toru Ishikawa

Kazuto Tajiri

机构：

[1] University Hospital of Cagliari,Medical Oncology

[2] IRCCS San Raffaele Hospital,Department of Medical Oncology

[3] Japanese Red Cross Himeji Hospital,Department of Internal Medicine

[4] Hokkaido University,Department of Gastroenterology and Hepatology, Graduate School of Medicine

[5] Kurume University School of Medicine,Division of Gastroenterology, Department of Medicine

[6] Kindai University Faculty of Medicine,Department of Gastroenterology and Hepatology

[7] CHA University School of Medicine,Department of Medical Oncology, CHA Bundang Medical Center

[8] University Hospital Frankfurt,Department of Internal Medicine 1

[9] Goethe University,Department of Medicine, Samsung Medical Center, School of Medicine

[10] Sungkyunkwan University,Department of Biomedical Sciences

[11] Humanitas University,Unit of Medical Oncology 2

[12] Humanitas Cancer Center,Department of Translational Research and New Technologies in Medicine and Surgery

[13] IRCCS Humanitas Research Hospital,Department of Oncology, ASAN Medical Center

[14] Liver Unit-CHTMAD,Oncology Unit 1

[15] University Hospital of Pisa,Division of Internal Medicine, Hepatobiliary and Immunoallergic Diseases

[16] University of Pisa,Department of Nursing

[17] University of Ulsan College of Medicine,Gastroenterology Center

[18] Veneto Institute of Oncology IOV-IRCCS,Division of Gastroenterology and Hepatology

[19] IRCCS Azienda Ospedaliero-Universitaria di Bologna,Dipartimento di Medicina Sperimentale e Clinica

[20] Gifu Kyoritsu University,Department of Oncology and Palliative Care, Cardinale G Panico

[21] Ehime Prefectural Central Hospital,Section of Gastroenterology and Hepatology, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, PROMISE

[22] Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano,Department of Internal Medicine

[23] Department of Hepatology,Division of Medical Oncology

[24] Università di Firenze,Department of Gastroenterology and Metabology

[25] Tricase City Hospital,Department of Gastroenterology

[26] University of Palermo,Department of Gastroenterology and Hepatology

[27] Ospedale per gli Infermi di Faenza,Division of Gastroenterology and Hepatology, Department of Internal Medicine

[28] Policlinico Universitario Campus Bio-Medico,Department of Hepatology

[29] Ehime University Graduate School of Medicine,Department of Gastroenterology

[30] Okayama City Hospital,Department of Gastroenterology

[31] Kagawa University,Center of Gastroenterology

[32] Nippon Medical School,Department of Gastroenterology

[33] Kagawa Prefectural Central Hospital,Department of Gastroenterology

[34] Asahi General Hospital,Hepato

[35] Osaka Medical and Pharmaceutical University,biliary Center

[36] Teine Keijinkai Hospital,Department of Gastroenterology and Hepatology

[37] Saiseikai Niigata Hospital,Department of Gastroenterology

[38] Toyama University Hospital,Division of Gastroenterology and Hepatology, Department of Internal medicine

[39] Japanese Red Cross Matsuyama Hospital,Department of Gastroenterology

[40] Ogaki Municipal Hospital,Department of Clinical Research

[41] Japanese Red Cross Takamatsu Hospital,Division of Gastroenterology and Hepatology

[42] Hyogo Medical University,Department of Hepatology

[43] Gunma Saiseikai Maebashi Hospital,Department of Surgery

[44] National Hospital Organization Takasaki General Medical Center,Department of Gastroenterology

[45] Otakanomori Hospital,Drug Development Unit

[46] Hamamatsu University School of Medicine,Department of Oncology

[47] Kansai Medical University,undefined

[48] National Hospital Organization Takasaki General Medical Center,undefined

[49] Sarah Cannon Research Institute UK,undefined

[50] IRCCS San Raffaele Scientific Institute Hospital,undefined

来源：

Journal of Cancer Research and Clinical Oncology | 2023年 / 149卷

关键词：

Advanced HCC; Atezolizumab plus bevacizumab; First-line therapy; Lenvatinib;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：5591 / 5602

页数：11

共 210 条

[1] Burgio V(2021)Real-life clinical data of lenvatinib versus sorafenib for unresectable hepatocellular carcinoma in Italy Cancer Manag Res 13 9379-9389
[2] Iavarone M(2021)Lenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: an inverse probability of treatment weighting analysis Liver Int 00 1-9
[3] Di Costanzo GG(2009)Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial Lancet Oncol 10 25-34
[4] Marra F(2022)Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma J Hepatol 76 862-873
[5] Lonardi S(2021)IMbrave150: Exploratory analysis to examine the association between treatment response and overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) J Clin Oncol 39 4071-2433
[6] Tamburini E(2020)Complete responses (CR) in patients receiving atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in IMbrave150: a phase III clinical trial for unresectable hepatocellular carcinoma (HCC) J Clin Oncol 38 4596-395
[7] Casadei-Gardini A(2021)Selection of first-line systemic therapies for advanced hepatocellular carcinoma: a network meta-analysis of randomized controlled trials World J Gastroenterol 27 2415-3728
[8] Scartozzi M(2020)Analyses of objective response rate, progression-free survival, and adverse events in hepatocellular carcinoma patients treated with lenvatinib: a multicenter retrospective study Hepatol Res 50 382-13
[9] Tada T(2019)Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions-multicenter analysis Cancer Med 8 3719-1192
[10] Yoo C(2021)Initial experience of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in real-world clinical practice Cancers 13 2786-1173

← 1 2 3 4 5 6 7 8 9 10 →